Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL9233865 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL6449725 | 0.94 | CA2 (0.50) | — | |
| Phosphoric Acid SCHEMBL29376065 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL28164910 | 0.94 | CA2 (0.50) | — | |
| Phosphoric Acid SCHEMBL29407043 | 0.94 | CA2 (0.50) | — | |
| Phosphoric Acid SCHEMBL8508281 | 0.94 | CA2 (0.50) | — | |
| Phosphoric Acid SCHEMBL30680372 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL9557773 | 0.94 | CA2 (0.50) | — | |
| Phosphoric Acid SCHEMBL9135273 | 0.94 | CA2 (0.50) | — | |
| Phosphoric Acid SCHEMBL29479504 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4232463-A | — | — | None | — | — | JP | disclosed |
| WO-2022042667-A1 | CARBON-SUPPORTED PLATINUM GROUP METAL CATALYST, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国石油化工股份有限公司 | 2022-03-03 | — | — | WO | disclosed |
| CN-110172045-A | A kind of preparation method for the intermediate being used to prepare Tianeptine sodium tablet | 甘肃皓天医药科技有限责任公司 | 2019-08-27 | — | — | CN | disclosed |
| US-9433637-B2 | Method for inhibiting influenza virus infection | KOBAYASHI PHARMACEUTICAL CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| CN-102438588-B | Methods of treating diseases using combination therapy | AMBIT BIOSCIENCES CORP | 2015-04-01 | — | — | CN | disclosed |
| US-20140350092-A1 | METHOD FOR INHIBITING INFLUENZA VIRUS INFECTION | Y'S CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8802641-B2 | Method for inhibiting onset of or treating pollen allergy | NATURA CORPORATION (JP) | 2014-08-12 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| CN-102438588-A | Methods of treating diseases using combination therapy | AMBIT BIOSCIENCES CORP | 2012-05-02 | — | — | CN | disclosed |
| CN-1613305-B | Active agent containing biological active substances from cony fur | WEISHI PHARMACEUTICAL RUGAO CO LTD | 2011-01-12 | — | — | CN | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090202601-A1 | METHOD FOR INHIBITING ONSET OF OR TREATING POLLEN ALLERGY | BBK BIO CORPORATION (JP) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| CN-101103019-A | 2- (Cyclic aminocarbonyl) indoline derivative and pharmaceutical composition containing same | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-01-09 | — | — | CN | disclosed |
| US-20060293263-A1 | Preparation for preventing contact of pathogenic matter with living organism | BBK BIO CORPORATION (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1625851-A1 | PREPARATION FOR PREVENTING CONTACT OF PATHOGENIC MATTER WITH LIVING ORGANISM | BBK Bio Corporation (JP) | 2006-02-15 | — | — | EP | disclosed |
| CN-1224420-C | Therapeutic agent for visual cell dysfunction | SUKANPO LTD (CH) | 2005-10-26 | — | — | CN | disclosed |
| CN-1613305-A | Cony fur containing biological active substances and use thereof | WEISHI PHARMACEUTICAL RUGAO CO (CN) | 2005-05-11 | — | — | CN | disclosed |
| CN-1352565-A | Agent for treating visual cell function disorder | R TECH UENO LTD (JP) | 2002-06-05 | — | — | CN | disclosed |
| JP-H04232463-A | COLLAGENASE-CONTAINING BUFFER LIQUID, ITS PREPARATION AND USE FOR DILUTING HUMAN SERUM | SCLAVO SPA | 1992-08-20 | — | — | JP | disclosed |